LAS CRUCES, NEW MEXICO / ACCESS Newswire / April 29, 2025 / As newly appointed CMS Administrator Dr. Mehmet Oz renews focus ...

VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media ...

Independent Surveys Rank Top ASC Vendors for Client Satisfaction and User Experience Across 18 Key Performance Indicators DENVER, CO / ACCESS Newswire / April 29, 2025 / Black Book Research, the ...

New manufacturing deal positions CBDL to tap into the $4.9 billion Latin American CBD market, unlocking major revenue growth ...

Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell ...

StudyAbivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis 29.04.2025 / 22:05 CET/CESTThe issuer is solely ...

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for ...

Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical ...

LOS GATOS, CA / ACCESS Newswire / April 29, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the extension of the ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...

In 2023, the myotonic dystrophy treatment market is projected to be worth USD 874.39 million. The global demand for myotonic dystrophy treatment is anticipated to increase at a CAGR of 12.3% between ...